Diabetes News

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health issues, recent data suggest they may improve brain health.

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes compared with younger adults, according to findings from a systematic review and meta-analysis published in JAMA.

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications consumed more than 80% of Medicare Part D spending, researchers reported.

Participants with metabolic syndrome who received 1,700 mg metformin daily with or without a Mediterranean diet intervention had reduced incidence of diabetes compared with placebo, according to findings published in Diabetes Care.

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and cardiovascular death among adults with type 2 diabetes and chronic kidney disease, Novo Nordisk announced.

The American Heart Association has issued the 2025 update to its annual heart disease and stroke statistics report, detailing recent trends in CV-related morbidity and mortality.

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March 29-31 in Chicago and online.

Regardless of age at diagnosis or duration of disease, patients with diabetes who underwent intensive glucose lowering had lower risk for vascular events and death, according to a post hoc analysis published in Diabetes Care.

High genetically predicted LDL was inversely associated with risk for incident diabetes, whereas the opposite trend was observed for CAD risk, researchers reported.